AU2015231076B2 - Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders - Google Patents

Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders Download PDF

Info

Publication number
AU2015231076B2
AU2015231076B2 AU2015231076A AU2015231076A AU2015231076B2 AU 2015231076 B2 AU2015231076 B2 AU 2015231076B2 AU 2015231076 A AU2015231076 A AU 2015231076A AU 2015231076 A AU2015231076 A AU 2015231076A AU 2015231076 B2 AU2015231076 B2 AU 2015231076B2
Authority
AU
Australia
Prior art keywords
liver
disorder
group
pharmaceutically acceptable
carboxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015231076A
Other languages
English (en)
Other versions
AU2015231076A1 (en
Inventor
Jeffrey C. Hanselman
Roger S. Newton
Rai Ajit K. Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esperion Therapeutics Inc
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of AU2015231076A1 publication Critical patent/AU2015231076A1/en
Application granted granted Critical
Publication of AU2015231076B2 publication Critical patent/AU2015231076B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015231076A 2014-03-20 2015-03-20 Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders Ceased AU2015231076B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461968082P 2014-03-20 2014-03-20
US61/968,082 2014-03-20
PCT/US2015/021677 WO2015143276A1 (en) 2014-03-20 2015-03-20 Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders

Publications (2)

Publication Number Publication Date
AU2015231076A1 AU2015231076A1 (en) 2016-09-22
AU2015231076B2 true AU2015231076B2 (en) 2020-05-21

Family

ID=54145365

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015231076A Ceased AU2015231076B2 (en) 2014-03-20 2015-03-20 Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders

Country Status (6)

Country Link
US (1) US20170209402A1 (enExample)
EP (1) EP3119388B1 (enExample)
JP (1) JP6633609B2 (enExample)
AU (1) AU2015231076B2 (enExample)
CA (1) CA2942100A1 (enExample)
WO (1) WO2015143276A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3370713A4 (en) * 2015-11-06 2019-10-23 Gemphire Therapeutics Inc. TREATMENT OF MIXED DYSLIPIDEMIA
WO2019179494A1 (zh) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 取代的十五烷二酸化合物及药物组合物及其用途
CN112675159A (zh) * 2021-01-12 2021-04-20 杭州师范大学 L-苹果酸在制备防治肝脏缺血再灌注损伤药物中的应用
WO2024212248A1 (en) * 2023-04-14 2024-10-17 Meta Pharmaceuticals (Hk) Limited Substituted alkanoic-diacids compound and composition and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067489A2 (en) * 2003-01-23 2004-08-12 Esperion Therapeutics, Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
WO2012040177A1 (en) * 2010-09-20 2012-03-29 Kareus Therapeutics, Sa Methods and compositions for treatment of diabetes and dyslipidemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067489A2 (en) * 2003-01-23 2004-08-12 Esperion Therapeutics, Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
WO2012040177A1 (en) * 2010-09-20 2012-03-29 Kareus Therapeutics, Sa Methods and compositions for treatment of diabetes and dyslipidemia

Also Published As

Publication number Publication date
EP3119388A1 (en) 2017-01-25
WO2015143276A1 (en) 2015-09-24
AU2015231076A1 (en) 2016-09-22
EP3119388A4 (en) 2017-11-22
EP3119388B1 (en) 2020-06-17
CA2942100A1 (en) 2015-09-24
JP6633609B2 (ja) 2020-01-22
US20170209402A1 (en) 2017-07-27
JP2017509701A (ja) 2017-04-06

Similar Documents

Publication Publication Date Title
EP3923970B1 (en) Methods for increasing growth in pediatric subjects having cholestatic liver disease
TWI735546B (zh) 使用fxr促效劑之方法
AU2013258566B2 (en) Pyrazole derivative and use thereof for medical purposes
KR102412997B1 (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
CN107072988A (zh) 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合
CN116726178A (zh) sGC刺激剂在非酒精性脂肪性肝炎（NASH）治疗中的应用
EP3119388B1 (en) Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders
US11834445B2 (en) Polymorphic forms of metopimazine
JP2019526644A (ja) Ｆｘｒアゴニストの組合せ
KR20150020160A (ko) 과민성 방광의 치료를 위한 무스카린 수용체 길항제 및 베타―3 아드레날린 수용체 작용제의 조합물
US20250170147A1 (en) Neuroactive steroids for treatment of gastrointestinal diseases or conditions
TW202308653A (zh) 以神經活性類固醇進行治療的方法
TW383222B (en) Pharmaceutical composition of bicycloheptane derivatives
CA3034956C (en) TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE
WO2026032004A1 (zh) 一种治疗帕金森综合征或帕金森病的方法和药物组合物
HK40113179A (zh) 以回肠胆汁酸转运蛋白(ibat)抑制剂治疗以增加无事件存活期(efs)
EP4618964A1 (en) Compositions and methods for treatment of prader-willi syndrome
HK40118603A (en) Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
HK40129994A (zh) 患有胆汁盐输出泵缺乏症的患者对asbti的基因型和剂量依赖性应答
HK40065058A (en) Methods for increasing growth in pediatric subjects having cholestatic liver disease
HK40065058B (en) Methods for increasing growth in pediatric subjects having cholestatic liver disease
HK40065061A (en) Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
HK40065061B (en) Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
WO2020094592A1 (en) Compounds for treating negative symptoms and cognitive impairments
HK40012462B (en) Treatment of nonalcoholic fatty liver disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired